---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-034473"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2026-02-03T23:59:59+00:00"
generated_at: "2026-05-16T05:20:52.382113+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Marvin White retires as Aptevo CEO; COO Jeff Lamothe named successor effective April 1, 2026

## Summary
- White to become Executive Chair; Lamothe promoted from COO to President and CEO and appointed to Board.
- John Niederhuber transitions from Chairman to Lead Independent Director; Board expands to seven directors.
- Lamothe receives $650K base salary, 60% bonus target, and a one-time $150K cash promotional award.
- Severance Plan modified to align Executive Chair benefits with CEO-level benefits; EVP tier removed.
- Company notes cash runway into 2029, $60M equity line, and clinical progress with mipletamig Phase 1b.

## SEC filing metadata
- accession: 0001193125-26-034473
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2026-02-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000119312526034473/0001193125-26-034473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000119312526034473/apvo-20260130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-034473
- JSON: https://secwatch.observer/filing/0001193125-26-034473.json
- Plain text: https://secwatch.observer/filing/0001193125-26-034473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.